We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Eden Research Plc | LSE:EDEN | London | Ordinary Share | GB0001646941 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.10 | -2.47% | 3.95 | 573,331 | 13:06:13 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 3.90 | 4.00 | 4.05 | 3.95 | 4.05 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 3.19M | -6.49M | -0.0122 | -3.24 | 21.6M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 13:07:02 | O | 40,000 | 3.926 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 13/1/2025 | 12:50 | ALNC |  TRADING UPDATES: Eden Research in revenue rise; Cordel gets UK deal |
| 13/1/2025 | 07:12 | UK RNS | Eden Research plc Trading Update |
| 20/12/2024 | 07:00 | UK RNS | Eden Research plc Regulatory approval for Novellus+ in Mexico |
| 16/12/2024 | 07:00 | UK RNS | Eden Research plc Appointment of Distributor in Austria |
| 11/12/2024 | 07:00 | UK RNS | Eden Research plc Mevalone Organic Input Registration in Germany |
| 07/11/2024 | 07:01 | UK RNS | Eden Research plc Trading Update |
| 07/11/2024 | 07:00 | UK RNS | Eden Research plc Ecovelex Approval in Italy |
| 08/10/2024 | 10:24 | UK RNS | Eden Research plc OTCQB exchange update |
| 23/9/2024 | 12:15 | ALNC | Eden Research half-year revenue surges nearly 75% despite rising costs |
| 23/9/2024 | 06:00 | UK RNS | Eden Research plc Half yearly Report |
Eden Research (EDEN) Share Charts1 Year Eden Research Chart |
|
1 Month Eden Research Chart |
Intraday Eden Research Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 15/1/2025 | 06:06 | Eden Research | 19,721 |
| 08/2/2024 | 07:42 | Eden....Onward and Upwards! | 52 |
| 21/6/2023 | 11:05 | The sterile garden of Eden | 123 |
| 29/3/2022 | 15:04 | Eden Research | 14 |
| 29/3/2022 | 13:36 | Eden Research - Who Is Behind Thallo Eco Products Corp? | 27 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2025-01-14 13:07:03 | 3.93 | 40,000 | 1,570.40 | O |
| 2025-01-14 13:05:52 | 3.91 | 255,764 | 10,005.49 | O |
| 2025-01-14 08:04:18 | 4.02 | 30,822 | 1,239.04 | O |
| 2025-01-14 08:00:32 | 4.06 | 246,745 | 10,005.51 | O |
| Top Posts |
|---|
Posted at 14/1/2025 08:20 by Eden Research Daily Update Eden Research Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 4.05p.Eden Research currently has 533,352,523 shares in issue. The market capitalisation of Eden Research is £21,067,425. Eden Research has a price to earnings ratio (PE ratio) of -3.24. This morning EDEN shares opened at 4.05p |
Posted at 04/1/2025 07:47 by investingisatrickygame Three key announcements this year to help propel value in Eden's share priceIn the 28th July 2023 Capital Raising RNS it clearly detailed the application of funds The Directors intend to use the net proceeds from the Firm Capital Raise and any proceeds from the Retail Offer for the following purposes: o Working capital to fund stock purchase for the Company's new seed treatment product DONE o Territory expansion (e.g. India, LATAM, SEA) for Mevalone and Cedroz REGULATORY SUBMISSIONS CERTAINLY DONE IN LATAM o Label expansion through lab screening, pot and field trials, formulation development etc for the Company's new seed treatment BEING PURSUED. WE ARE ALREADY AWARE OF SUNFLOWERS. NO DOUBT OTHERS ARE BEING CONSIDERED o Expand commercial team with commercial director and market development /Product Manager DONE The Directors intend to use the net proceeds from the Conditional Capital Raise for the following purposes: o Additional seed treatment label expansions AS ABOVE o Insecticide label expansions WE WAIT TO SEE o New product development o US based team So aside of a US team, that leaves New Product Development (NPD). We all know in Eden's world this takes many years, if successful and many more if not. So the immediate path (next 2 years) to shareholder value is clear. 1)Regulatory approval of existing known products, both in new territories and first time approvals using existing active ingredients, already widely approved. 2)Label extensions of existing products in existing territories. 3)Increased sales. All appear to me to be a given and if correct, 4p is going to be a distant memory as something much higher becomes the norm, this year. For what is or has been a difficult story to sometimes understand, understanding Eden now, has become far simpler as has the visibility to future shareholder value, which is far more near-term than ever. |
Posted at 21/11/2024 09:31 by ravenna23 To all new investors whose interest has been drawn by the recent share price increase, beware. Edens share price rockets, on no significant news, when a capital raising is on the way. Then it collapses to lower lows. Why, because they don't actually sell anything. |
Posted at 10/11/2024 08:22 by supersonico Stone Fruits;"There is significant future potential to expand the use of Mevalone for the treatment of powdery and downy mildews and field trials for these applications on grapes are currently underway, with the potential to expand further to include crops such as berries and stone fruits. All expanded uses of Mevalone are, as always, subject to regulatory approval, which is anticipated in the coming years" .................... Investingisatrickyga It does imply that this approval will lead to other regulators viewing this and actioning the same. I'm looking at Almonds in California! Investingisatrickyga California produces 80% of the world's Almonds and is 100% of US production. Californian Almond crop production is expected to be 21% higher in 2024 over 2023. Almonds are California's 3rd most valuable crop. I fully expect Sipcam to get that label extension. .................... Biofungicide Label Extension in Spain 24 June 2024 This newly expanded label makes Araw one of the most versatile and reliable solutions to prevent fungal diseases in many crops under organic and conventional agriculture. Thanks to this new authorisation, obtained through Sipcam's local regulatory team, all relevant horticultural crops in Spain can now be protected with Araw representing an excellent opportunity in several crops of growing importance, such as avocado, mango, and almond, which has become the third largest tree crop in Spain after olives and grapes. Spain boasts the largest cultivated area of almond trees in the world and ranks third in terms of overall production. Eden anticipates that this growth of the addressable market for Araw will contribute to revenue in 2025 and beyond. Further details of this expansion will be provided in due course as commercialisation commences. Sean Smith, Chief Executive Officer of Eden Research, commented: "Today's announcement is an excellent demonstration of our strategy to pursue growth opportunities through both new product introductions and with existing products by targeting new crop types and new disease targets. We are delighted to build on the success of our longstanding relationship with Sipcam. They have done an outstanding job of making the Iberian region an important and strong revenue-generating territory for the Company. This label extension represents a significant additional growth opportunity for us. It not only includes numerous new crops and diseases, but it also includes a number of high-value crops that are particularly disease prone." |
Posted at 10/11/2024 08:14 by supersonico 15 December 2022Eden Research Plc ("Eden" or "Company") Distribution Agreement for Mevalone in France Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, announces that it has signed an agreement ("Agreement") with Corteva France ("Corteva") which allows Corteva to market, distribute and sell Eden's fungicide product, Mevalone®, in France on an exclusive basis. Mevalone is Eden's flagship, sustainable, foliar biofungicide, which is used to treat Botrytis cinerea on grapes and various other crops, a fungal disease commonly found in crops exposed to humid conditions. Eden also recently received authorisation for the use of Mevalone on pome fruits, including apples and pears, in France to help treat post-harvest diseases that arise during storage, thereby significantly reducing food waste. .................... There is significant future potential to expand the use of Mevalone for the treatment of powdery and downy mildews and field trials for these applications on grapes are currently underway, with the potential to expand further to include crops such as berries and stone fruits. All expanded uses of Mevalone are, as always, subject to regulatory approval, which is anticipated in the coming years. .................... France is widely recognised for its agricultural output, which is well-known for its high quality. France's vineyards are the country's biggest consumers of plant protection products, which include fungicides, insecticides, and herbicides. Although viticulture represents just 3% of France's agricultural land, the sector consumes 20% of the country's fungicides. It also represents 15% of French agricultural produce in value terms; an exciting landscape in which Eden's biopesticides will play an expanded role. The Agreement with Corteva will be implemented immediately with commercial progress expected over the course of the next year as Eden transitions from its current distribution arrangements. Sean Smith, CEO of Eden Research plc, commented: "Expanding our partnership with agriscience powerhouse Corteva reflects the further execution and acceleration of Eden's commercial strategy. Eden has a strong existing partnership with Corteva with our ongoing collaboration around the development of seed treatments, and this Agreement marks the expansion of our relationship with the focus of this Agreement being to increase Eden's commercial presence in the all-important French grape and pome fruits markets. "Corteva's vast presence in France will enable Eden to capitalise on the significant commercial opportunities that exist within this expansive market and has strong potential to increase Eden's product sales revenue. Coupled with our recently received EPA approval in the US, this Agreement highlights the global demand for sustainable biopesticides and the strides Eden is making to broaden its global footprint and accelerate commercial growth." Sylvain Bedel, Managing Director of Corteva France said: "We are pleased to be expanding our working relationship with Eden by supplying to farmers Eden's innovative bio-solutions in the French market. There is a strong demand for more sustainable growing practices in France and farmers are paying increasing attention to consumer demand for such practices. Eden's unique technology helps provide a much-needed solution." |
Posted at 08/11/2024 10:40 by investingisatrickygame Alchemy,So Cavendish has a target of 20p and Eden say's in their opinion the shares are worth north of 20p. This is as of today. It doesn't take account of a full Ecovelex approval, an insecticide partner(s) and a Powdery Mildew approval in France for Esseva delivering up to 10* greater revenue than Mevalone treating Botrytis. It all adds up to a bargain share price of currently, 3.7p. So for those following the story, it offers a time to accumulate where desired and reassurance for those that are tapped out. To remind us, Ecovelex is a €33.8 million opportunity. As the Trading Update RNS stated yesterday, "However, the opportunity for the insecticide product could well surpass anything else we have done to date, and this is exciting for all of us." In other words, in my opinion, financial numbers stated in Eden presentations are likely understated. No cash needed! Question: What will Cavendish's price target be when these RNS's are delivered (expected soon according to Eden) and what will managements view of share price be at that stage? 3.7p is a ridiculous opportunity to invest in Eden with three triggers so close. |
Posted at 07/11/2024 22:12 by supersonico Second Ecovelex 2024 Approval announced ~6 weeks earlier than 2023.Full EU🧑&# .................... Eden Research and Corteva Agriscience Announce Ecovelex?2023 Approval in Italy Cremona, Italy and Abingdon, UK - December 18, 2023 - Corteva Agriscience and Eden Research are pleased to announce that Ecovelex? 2023 has been granted, according to Reg. EU/1107/2009, a temporary approval in Italy for use as a bird repellent seed treatment in corn for the 2024 growing season. Eden is an AIM listed company that develops and supplies sustainable solutions for crop protection, animal health and consumer products. ............. Ecovelex Approval in Italy 07 November 2024 Eden Research plc ("Eden") is pleased to announce that Ecovelex™ 2024 has been granted, according to Reg. EU/1107/2009, approval in Italy for use as a bird repellent seed treatment in corn for the 2025 growing season. Eden is a leader in sustainable biopesticide and biocontrol products and technologies. |
Posted at 05/11/2024 13:29 by neutralpov Eden share price Chart indeed coiled like a spring.Aimed DOWNWARDS. Trump's impending victory in PA and elsewhere will be one of the final nails in the biocoffin of this "very bio" stock. Very bio, as in, just like faeces. |
Posted at 20/10/2024 11:26 by investingisatrickygame Alchemy said"* I was told that but how much looking ahead is being done at 3.9p?" Very, very little in my opinion, hence 3.9p! The growth in sales is down to the distributors. Eden has done its job in the respect that it has developed products that distributors want and regulators are approving. Ecovelex was required by Corteva, is required by farmers and has been jointly developed between Eden and Corteva. When that full regulatory approval comes, so will the sales, likely "in short order" :). That will be a trigger of awareness that will see 3.9p as a distant memory. Of course, before that RNS comes, an insecticide announcement could come and that could blow the bloody doors off as Michael Caine might say. So we have 2 share price triggers. Both should attract the minds of private investors, institutional investors and the press. And of course, there is the French PM/DM regulatory submission awaiting approval which will has a fast impact on revenue. Anyone of the above could within the year, put Eden into profit. Question is, how much? French approval 'could' come pre-Christmas, who knows. Corteva took control of France and Mevalone in December 2022 with regulatory label extensions due to be submitted thereafter We have been told several times that regulatory approval in the US will be more expedient now with the AI's and Sustaine already approved, so the US could be approving the insecticide ready for sale sometime in 2025 AND, Corteva has more than implied, on film, that Exovelex will be on sale in the EU in 2025. One could assume it is possible that, all 3 could make a contribution to revenue and profit in 2025. If this is understood more widely and comes to be, our share price will be, hopefully, many, many multiples of circa 4p If you view things this way, an investment in Eden now seems a total no brainer. |
Posted at 12/10/2024 13:21 by investingisatrickygame Timbo_SliceI'm sure Directors don't have endless pots of money, especially those in AIM companies; why would they. There seems to be a perception that this job status means you're loaded and can buy tens if not hundreds of thousands of pounds worth of shares at any given time. Surely that can't be true?! Options are fine as long as they are geared and aligned to shareholder success. Eden specifically is an enabler, is it not. They are enabling sales distributors to provide solutions to farmers that they themselves have not developed, at least not as successfully as they current Eden products on sale. The natural progression to that is to deepen the relationship and ask if Eden can develop other solutions to other problems. This we see happening. Eden is almost like a flower. It has been planted and is just waiting for its season to bloom and when it does, it will open up in full colour and size. This, in my opinion, is what will happen with the share price (hopefully). From nothing to something substantial. |
Posted at 08/10/2024 12:06 by money never sleeps The aptly named "Hurricane Milton" descends on Florida just as Milton Park braces itself for an Eden share price storm. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
